接受Aficamten治疗的梗阻性肥厚型心肌病患者中标准治疗药物的撤药情况:FOREST-HCM研究
FOREST-HCM开放标签研究纳入145例梗阻性肥厚型心肌病患者,其中136例(93.8%)接受至少一种标准治疗药物。64例(47%)尝试减量或撤药,59例(92.2%)成功;撤药后纽约心功能分级、堪萨斯城心肌病问卷评分、左室流出道压差及生物标志物均改善,且未因撤药出现严重不良事件。
要点
- 接受Aficamten治疗且病情稳定的oHCM患者中,近半数可尝试标准治疗药物减量或撤药,成功率较高。
- 成功撤药后心功能、生活质量、左室流出道压差及生物标志物持续改善,与未撤药者相似。
- 撤药后未见相关严重不良事件,治疗中出现的不良事件两组相似。
核心结论
- 在FOREST-HCM研究中,接受Aficamten治疗的oHCM患者中约一半尝试标准治疗药物减量或撤药,多数成功且很少需要恢复用药。
- 停用或减量标准治疗药物耐受良好,对临床疗效指标无不良影响。
研究设计与样本
- FOREST-HCM(NCT04848506)为开放标签、随访研究,纳入145例接受Aficamten治疗至少24周的oHCM患者。
- 患者在接受稳定剂量Aficamten≥4周后,由研究者决定按方案尝试标准治疗药物减量或撤药。
- 成功撤药定义为至少一种药物剂量减少≥50%;撤药后1–2周前瞻性评估不良事件。
主要发现
- 136例(93.8%)接受至少一种标准治疗药物;64例(47%)尝试撤药,59例(92.2%)成功。
- 成功撤药者中79.2%纽约心功能分级较基线改善≥1级,堪萨斯城心肌病问卷临床总结评分改善至83.0±15.8分。
- 成功撤药者静息和Valsalva左室流出道压差分别改善至14.3±10.9和32.9±21.4 mm Hg。
- N末端B型利钠肽前体改善至中位数220.0 pg/mL(Q1-Q3:102.0-554.0 pg/mL),高敏肌钙蛋白I改善至中位数6.0 ng/L(Q1-Q3:3.5-10.7 ng/L)。
关键数值与推荐
- 成功撤药定义为至少一种标准治疗药物剂量减少≥50%。
- 撤药后1–2周前瞻性评估不良事件。
- 减量或撤药对疗效指标变化无显著影响(所有变化P值>0.05),且与未撤药者相似。
- 无因撤药导致的严重不良事件,治疗中出现的不良事件两组相似。
临床怎么用
- 对于接受Aficamten治疗且病情稳定的oHCM患者,可考虑在研究者指导下尝试标准治疗药物减量或撤药。
- 撤药后应短期(1–2周)评估不良事件,并监测心功能、左室流出道压差及生物标志物变化。
局限性
- 本研究为开放标签设计,未设对照组,减量或撤药由研究者决定,可能存在选择偏倚。
- 样本量有限,且随访时间至少24周,长期撤药的安全性和获益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects. OBJECTIVES: We describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy; NCT04848506). METHODS: Patients receiving SoC therapy (beta-blocker, nondihydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC downtitration and withdrawal at the discretion of the investigator and after achieving a stable dose of aficamten for ≥4 weeks. Successful SoC withdrawal was defined as at least a 50% dose-reduction in ≥1 medication. Adverse events (AEs) were prospectively evaluated 1 to 2 weeks after any SoC withdrawal. RESULTS: Of 145 patients with oHCM who were followed for at least 24 weeks (mean age 60.5 ± 13.2 years; 44.8% female; 42% NYHA functional class III), 136 (93.8%) were receiving ≥1 SoC therapy; of those, 64 (47%) had an attempt at withdrawal, with 59 (92.2%) successful. Thirty-eight (64.4%) patients completely discontinued ≥1 medication, and 27 (45.8%) achieved aficamten monotherapy with 2 later restarting a SoC medication. There were no significant differences in baseline characteristics on day 1 in FOREST-HCM in those with a SoC-withdrawal vs no-withdrawal attempt. In patients who underwent successful SoC therapy withdrawal, NYHA functional class improved by ≥1 class in 79.2% from baseline, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score improved to 83.0 ± 15.8 points, and resting and Valsalva left ventricular outflow tract gradient improved to 14.3 ± 10.9 and 32.9 ± 21.4 mm Hg, respectively. N-terminal pro-B-type natriuretic peptide levels improved to a median of 220.0 pg/mL (Q1-Q3: 102.0-554.0.0 pg/mL) and high-sensitivity troponin I improved to a median of 6.0 ng/L (Q1-Q3:3.5-10.7 ng/L). Downtitration and withdrawal of SoC therapy did not impact these results (all P values for change were >0.05), and these changes were similar in patients who did not undergo SoC therapy withdrawal. There were no serious AEs attributed to SoC withdrawal and treatment emergent AEs were similar between groups. CONCLUSIONS: In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506).
引用
- Masri A, Choudhury L, Barriales-Villa R, et al. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024. PMID: 39477631. doi:10.1016/j.jacc.2024.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。